WPA has clarified its attitude to the use of drugs in treating cancer.
The company accepts the use of biological drugs Herceptin and Avastin.
Up to 20 advanced anti-cancer agents could become available over the next 18 months, some costing £100,000 per patient.
More than a dozen such drugs have already been licensed for use – but are still unavailable to NHS patients.
These drugs are available to those insured under WPA policies.
Patients are entitled to mix and match by hopping between private and NHS treatment.
WPA will cover the new high cost advanced targeted cancer therapeutics.
WPA recognises the merit in these new treatments and funds their use.
The use of these drugs is already leading to higher claims payouts and inevitable will mean increased premiums.